At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Clinicians from University of Chicago Medicine, Northwestern Medicine, and Loyola Medicine said bispecific antibodies for early-relapse myeloma can be given safely outside the hospital, but staffing, after-hours triage, and community confidence have yet to catch up.

Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.

Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.

The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.

Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.